Department of Cardiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Cardiovascular Key Lab of Zhejiang Province, Hangzhou, China.
J Cell Mol Med. 2021 Jun;25(12):5351-5357. doi: 10.1111/jcmm.16566. Epub 2021 May 4.
Despite the great progress made in the treatment for cardiovascular diseases (CVDs), the morbidity and mortality of CVDs remains high due to the lack of effective treatment strategy. Inflammation is a central pathophysiological feature of the heart in response to both acute and chronic injury, while the molecular basis and underlying mechanisms remains obscure. Interleukin (IL)-13, a pro-inflammatory cytokine, has been known as a critical mediator in allergy and asthma. Recent studies appraise the role of IL-13 in CVDs, revealing that IL-13 is not only involved in more obvious cardiac inflammatory diseases such as myocarditis but also relevant to acute or chronic CVDs of other origins, such as myocardial infarction and heart failure. The goal of this review is to summarize the advancement in our knowledge of the regulations and functions of IL-13 in CVDs and to discuss the possible mechanisms of IL-13 involved in CVDs. We highlight that IL-13 may be a promising target for immunotherapy in CVDs.
尽管在心血管疾病 (CVD) 的治疗方面取得了巨大进展，但由于缺乏有效的治疗策略，CVD 的发病率和死亡率仍然很高。炎症是心脏对急性和慢性损伤的一种核心病理生理特征，而分子基础和潜在机制尚不清楚。白细胞介素 (IL)-13 是一种促炎细胞因子，已被认为是过敏和哮喘的关键介质。最近的研究评估了 IL-13 在 CVD 中的作用，揭示了 IL-13 不仅参与更明显的心脏炎症性疾病，如心肌炎，而且与其他来源的急性或慢性 CVD 相关，如心肌梗死和心力衰竭。本综述的目的是总结我们对 IL-13 在 CVD 中的调节和功能的认识，并讨论 IL-13 参与 CVD 的可能机制。我们强调，IL-13 可能是 CVD 免疫治疗的一个有前途的靶点。
